Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie

DRUG3 trials

Sponsors

Iovance Biotherapeutics Inc., Universitair Ziekenhuis Gent

Conditions

MelanomaMelphalan and ATG.Patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapyPatients undergoing allogeneic HSCTfollowing RIC with Fludarabinefor hematological malignancy

Phase 3

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma

RecruitingCTIS2022-503140-41-00

Iovance Biotherapeutics Inc.Melanoma

Start: 2024-11-29Target: 280Updated: 2025-10-31

Phase 4

Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium

RecruitingCTIS2023-503723-26-00

Universitair Ziekenhuis Gentfollowing RIC with Fludarabine, for hematological malignancy, Melphalan and ATG. +1

Start: 2025-06-04Target: 50Updated: 2025-06-11

Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy

Not yet recruitingCTIS2025-524278-40-00

Universitair Ziekenhuis Gentfor hematological malignancy, Patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy

Target: 75Updated: 2026-03-23